Skip to content

Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus

Pilot Study: Dose Dependent Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01908348
Enrollment
27
Registered
2013-07-25
Start date
2013-07-18
Completion date
2016-12-31
Last updated
2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Erythritol, Endothelial function

Brief summary

This study is an open-label pilot designed to examine the dose-dependent effects of erythritol, a zero calorie sweetener, on endothelial function. Twenty-four subjects with type 2 diabetes mellitus will make three study visits. At each visit, the will consume an orange-flavored beverage containing escalating amounts of erythritol (6, 12, and 18 grams). Endothelial function will be assessed before and two hours after beverage consumption. Endothelial function will be measured as the change in pulse amplitude in response to reactive hyperemia measured in the fingertip by peripheral arterial tonometry. The results will be used to plan a randomized, placebo-controlled study.

Interventions

DIETARY_SUPPLEMENTErythritol

Sponsors

Cargill
CollaboratorINDUSTRY
Boston University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male and Female subjects * Otherwise healthy patients with Type 2 diabetes mellitus as defined by fasting blood glucose \>125 mg/dl or with ongoing treatment for Type 2 diabetes mellitus with the exception of insulin.

Exclusion criteria

* Women with a positive urine pregnancy test * Body mass index \>35 kg/m2 * Current daily long-acting insulin therapy (short acting, insulin as needed is not an exclusion). * Clinical history of other major illness including cancer, renal failure, hepatic failure, or other conditions that in the judgment of the principal investigator make a clinical study inappropriate. * Treatment with an investigational drug within the last twelve weeks * History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study. * Treatment with vitamin E, vitamin C, and beta carotene, lipoic acid, and other food or herbal supplements within 1 month of enrollment. Subjects taking multivitamins or other forms of vitamin E and C in doses that do not exceed two times the recommended daily allowance will not be excluded. * Recent change in diet or level of physical activity that in the judgment of the investigators would be likely to affect endothelial function (to be evaluated on a case by case basis). * Ongoing illicit drug use or alcohol abuse. * Sensitivity/intolerance to dietary polyols.

Design outcomes

Primary

MeasureTime frameDescription
Endothelial function2 hoursChange in pulse amplitude in the fingertip in response to reactive hyperemia measured by peripheral arterial tonometry.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026